

Special Issue

Glioblastoma Stem Cells: Molecule Pathways and Cancer Therapy

Message from the Guest Editor

The primary goal of this Special Issue is to gather cutting-edge research and reviews that advance our understanding of GSCs, their role in the progression of glioblastoma, and potential therapeutic strategies targeting these cells. Research areas may include (but are not limited to) the following:

- Studies exploring GSCs which have focused on understanding their molecular and genetic characteristics, identifying specific markers for their isolation and targeting, and uncovering their origin and evolution within the GBM tumor microenvironment.
- Explorations of key signaling pathways that have revealed their crucial roles in regulating the self-renewal, differentiation, and survival of GSCs.
- Studies on the development of novel drugs and therapies targeting GSC populations, focusing on modulating GSC-related pathways to improve the effectiveness of existing treatments like chemotherapy, radiotherapy, immunotherapy, and gene therapy.
- Research on GSCs that examines how the tumor microenvironment, including immune cells, stromal cells, and extracellular matrix components, influences GSC behavior and resistance.

Guest Editor

Dr. Shilpi Singh

Department of Neurosurgery, University of Minnesota, Minneapolis, MN, USA

Deadline for manuscript submissions

closed (31 March 2026)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/220757

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)